Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Mississippi Woman Suffers from Femur Fracture after Taking Fosamax and Files Lawsuit Alleging Merck’s Bone Loss Drug Caused the Thigh Break

July 14, 2012

Parker Waichman LLP has filed a lawsuit on behalf of a woman who suffered a left atypical femur fracture, allegedly due to using Fosamax (alendronate). Fosamax is part of a class of drugs known as bisphosphonates, which studies have linked to large bone fractures.

New York, NY (PRWEB) July 13, 2012

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit alleging that Fosamax caused a left femur fracture and other subsequent complications in a Mississippi woman. The suit was filed on June 29th in the Superior Court of New Jersey, Atlantic County Law Division (Case No. L4568-12). Merck Sharp & Dohme Corp. and Merck & Co., Inc. have been named as Defendants.

According to the complaint, the Plaintiff starting taking Fosamax as prescribed in December 2005. In July 2010, she suffered from a left subtrochanteric femur fracture. The suit alleges that the Plaintiff also endured severe mental and physical pain and suffering, permanent injuries, emotional distress, economic loss due to medical expenses and living related expenses due to a new lifestyle.

The lawsuit further alleges that the Plaintiff´s injuries are a result of using Fosamax for several years. The suit also claims that the Plaintiff would never have taken the drug if she were fully informed about the risks. Allegedly, Defendants knew that taking Fosamax could result in severely suppressed bone turnover and multiple stress fractures, but did not adequately warn consumers or the public.

The U.S. Food and Drug Administration approved Fosamax to prevent bone loss due to osteoporosis. Fosamax, along with other drugs like Actonel and Boniva, is a part of a class of drugs known as bisphosphonates. In October 2010, the FDA updated the label on Fosamax, Fosamax Plus D and other bisphosphonates, warning about the risk of atypical femur fractures.

In addition to atypical femur fractures, bisphosphonates have also been linked to osteonecrosis of the jaw (ONJ) and esophageal cancer.

Recently, the FDA published data suggesting that there may be no benefit to taking Fosamax and its sister drugs on a long-term basis. After reviewing data from 2,342 women the agency stated that there is “little benefit of continued bisphosphonate treatment beyond 5 years.”

Another recent study published in the Archives of Internal Medicine found that 82 percent of patients with atypical femur fractures had been taking bisphosphonates.

Parker Waichman LLP continues to offer free legal consultations to victims of Fosamax side effects. If you or a loved experienced an atypical femur fracture and you believe Fosamax is to blame, please contact their office by visiting the firm´s Fosamax website. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding Fosamax side effects lawsuits and Parker Waichman LLP, please visit: yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).

Contact:

Parker Waichman LLP

Gary Falkowitz, Managing Attorney

(800) LAW-INFO

(800) 529-4636

yourlawyer.com

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebfosamaxfemurfractures/72012/prweb9696473.htm


Source: prweb